Mylan-Amlodipine 5.0 mg – DIN 02272113
Mylan-Amlodipine is Amlodipine Besylate 5.0 mg (tablet), sold in Canada. It is used for high blood pressure and heart disease. It is supplied by Mylan Pharmaceuticals ULC. We don't have a photo or description of what this pill looks like yet, so check the name and code on the box or bottle, and ask a pharmacist before taking it. Its official Health Canada listing links to the product monograph, which describes the tablets.
Sold in Canada
Amlodipine Besylate 5.0 mg
- Brand
- Mylan-Amlodipine
- Strength
- 5.0 mg
- Used for
- High blood pressure and heart disease
- Form
- Tablet
- Manufacturer
- Mylan Pharmaceuticals ULC
- Drug class
- Calcium channel blocker (blood pressure and heart medicine)
- Sold in
- Canada
- DIN
- 02272113
Source: Health Canada's Drug Product Database. Last checked .
Report a mistake
What is Amlodipine Besylate used for?
Amlodipine Besylate is used for high blood pressure and heart disease.
- Medicine type
- Calcium channel blocker (blood pressure and heart medicine)
Official uses from the US prescribing label
Hypertension
Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Amlodipine besylate tablets.
Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.
Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.
Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.
Amlodipine besylate tablets may be used alone or in combination with other antihypertensive agents.
Coronary Artery Disease (CAD)
Chronic Stable Angina Amlodipine besylate tablets is indicated for the symptomatic treatment of chronic stable angina. Amlodipine besylate tablets may be used alone or in combination with other antianginal agents.
Vasospastic Angina (Prinzmetal’s or Variant Angina) Amlodipine besylate tablets is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine besylate tablets may be used as monotherapy or in combination with other antianginal agents.
Angiographically Documented CAD In patients with recently documented CAD by angiography and without heart failure or an ejection fraction <40%, Amlodipine besylate tablets is indicated to reduce the risk of hospitalization for angina and to reduce the risk of a coronary revascularization procedure.
From the FDA-approved label on DailyMed (published Oct 05, 2026).
Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.
Is this your medicine? Check the box
- The box or bottle shows DIN 02272113.
- It names Mylan-Amlodipine, Amlodipine Besylate 5.0 mg.
- A loose pill is a different matter: without a description of its markings, a pharmacist has to confirm what it is.
Sold in Canada as Mylan-Amlodipine by Mylan Pharmaceuticals ULC.
In Canada: prescription only.
Ingredients
Active: Amlodipine (Amlodipine Besylate)
Other Amlodipine Besylate pills
-
209
Amlodipine Besylate 10 mg
White, round, 11 mm
Used for high blood pressure and heart disease
-
Al0
Amlodipine Besylate 10 mg
White, round, 3 mm
Used for high blood pressure and heart disease
-
210
Amlodipine Besylate 5 mg
White, round, 8 mm
Used for high blood pressure and heart disease
-
A5
Amlodipine Besylate 5 mg
White, round, 2 mm
Used for high blood pressure and heart disease
- K 320 Amlodipine Besylate White, round, 6 mm Used for high blood pressure and heart disease
- K 321 Amlodipine Besylate White, round, 8 mm Used for high blood pressure and heart disease
- K 322 Amlodipine Besylate White, round, 12 mm Used for high blood pressure and heart disease
- ADP bes 2.5 Amlodipine Besylate White, triangle, 7 mm Used for high blood pressure and heart disease